Novacyt S.A (NCYT) is a leading diagnostics & research business based in the UK. It opened the day at 516.52p after a previous close of 517.44p. During the day the price has varied from a low of 510p to a high of 594.84p. The latest price was 524p (25 minute delay). Novacyt is listed on the London Stock Exchange (LSE) and employs 110 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Novacyt's share price has had significant positive movement.
Its last market close was 929p, which is 88.70% up on its pre-crash value of 105p and 2,996.46% up on the lowest point reached during the March crash when the shares fell as low as 30.002p.
If you had bought £1,000 worth of Novacyt shares at the start of February 2020, those shares would have been worth £3,350.52 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £19,154.68.
|52-week range||6.5p - 980p|
|50-day moving average||499.4572p|
|200-day moving average||357.2447p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-26.2p|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2020-11-17)||-34.01%|
|1 month (2020-10-23)||-56.11%|
|3 months (2020-08-24)||73.22%|
|6 months (2020-05-22)||63.75%|
|1 year (2019-11-22)||4,890.48%|
|2 years (2018-11-23)||1,397.14%|
|3 years (2017-11-24)||799.57%|
Valuing Novacyt stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novacyt's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novacyt's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Novacyt shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||£8.3 million|
|Return on assets TTM||49.17%|
|Return on equity TTM||97.09%|
|Market capitalisation||£679.9 million|
TTM: trailing 12 months
We're not expecting Novacyt to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Novacyt's shares have ranged in value from as little as 6.5p up to 980p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Novacyt's is -2.8374. This would suggest that Novacyt's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Novacyt has bucked the trend.
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.
Ever wondered how to buy shares in Wilmington? We explain how and compare a range of providers that can give you access to many brands, including Wilmington.
Ever wondered how to buy shares in Vertu Motors? We explain how and compare a range of providers that can give you access to many brands, including Vertu Motors.
Ever wondered how to buy shares in Tribal Group? We explain how and compare a range of providers that can give you access to many brands, including Tribal Group.
Ever wondered how to buy shares in Time Out Group? We explain how and compare a range of providers that can give you access to many brands, including Time Out Group.
Ever wondered how to buy shares in SigmaRoc? We explain how and compare a range of providers that can give you access to many brands, including SigmaRoc.
Ever wondered how to buy shares in Inspecs Group? We explain how and compare a range of providers that can give you access to many brands, including Inspecs Group.
Ever wondered how to buy shares in Symphony International Holdings? We explain how and compare a range of providers that can give you access to many brands, including Symphony International Holdings.
Ever wondered how to buy shares in Sigma Capital Group? We explain how and compare a range of providers that can give you access to many brands, including Sigma Capital Group.
Ever wondered how to buy shares in Sensyne Health? We explain how and compare a range of providers that can give you access to many brands, including Sensyne Health.
Ever wondered how to buy shares in Scancell Holdings? We explain how and compare a range of providers that can give you access to many brands, including Scancell Holdings.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.